These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 27825133)

  • 1. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SP1 upregulated FoxO3a promotes tumor progression in colorectal cancer.
    Yu Y; Peng K; Li H; Zhuang R; Wang Y; Li W; Yu S; Liang L; Xu X; Liu T
    Oncol Rep; 2018 May; 39(5):2235-2242. PubMed ID: 29565456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
    Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
    Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
    Wu Z; Huang M; Gong Y; Lin C; Guo W
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
    Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
    Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
    Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
    Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
    Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
    Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
    Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
    Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
    Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
    PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
    Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
    Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.
    Chandramohan V; Mineva ND; Burke B; Jeay S; Wu M; Shen J; Yang W; Hann SR; Sonenshein GE
    J Cell Biochem; 2008 Aug; 104(6):2091-106. PubMed ID: 18393360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.